Members directory

AIS Biotech is a French biotech company, incorporated in March 2023 and based in the Alps, focused on the development of a new class of anti-infective biotherapies.The company aimed at combating (re)emerging infectious diseases. Leveraging a sustainable bioengineering platform and the expertise of a leading academic laboratory, CERMAV (CNRS, Grenoble, France), Our ambition is to develop a pipeline of cutting-edge sugar-based anti-infective biopharmaceuticals. By mimicking the natural binding sites of pathogens on the host cell surface, AIS Biotech’s compounds act as decoy receptors, preventing or treating infections. The company’s first drug candidate, GlycoFlu, is designed to prevent or treat infections caused by human influenza viruses. Influenza represents a major global public health challenge, with significant socio-economic impacts. With GlycoFlu, AIS Biotech aims to address this critical public health issue, and more generally, contribute to the fight against infectious diseases and Antimicrobial Resistance.